Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8mL dose.

Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

The US Food and Drug Administration (FDA) has approved Bavarian Nordic’s chikungunya vaccine Vimkunya for use in individuals ...

With the U.S. FDA’s approval of Vimkunya, Bavarian Nordic A/S is now in the chikungunya virus infection mix along with Valneva SE’s Ixchiq. A single-dose, adjuvanted virus-like particle-based vaccine ...

As a bonus, Bavarian Nordic also gets a priority review voucher from the FDA, awarded as an incentive to carry out drug ...

Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger ...

Bavarian Nordic (OTCPK:BVNRY) has received FDA approval for its vaccine Vimkunya for the prevention of chikungunya. The virus-like particle, or VLP, vaccine is approved for people aged 12 and older.

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers.On track for commercial launch in the U.S. in the ...

The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...

Valneva (VALN) stock gained as its chikungunya vaccine receives marketing authorization in the U.K., expanding the single-dose shot's global reach. Read more here.